分析地西他滨治疗骨髓增生异常综合征临床效果及安全性

Analysis of Clinical Efficacy and Safety of Decitabine in the Treatment of Myelodysplastic Syndrome

目的了解骨髓增生异常综合征患者用地西他滨进行治疗对病情的控制作用以及不适症状发生情况。方法纳入本院2014年至2017年收治骨髓增生异常综合征患者为分析对象,随机抽取12例并根据其入院时间先后将其每组6例分为对照组与观察组,对照组用传统化疗干预,观察组用地西他滨药物治疗。比较两种方案对骨髓增生异常综合征患者的应用价值。结果疗程后评价两种方案的干预价值,观察组有效率为83.3%,对照组有效率为66.7%,观察组有优越性但组间差异无统计学意义(P> 0.05),但在缓解率方面观察组有显著优越性(P<0.05);在各种不良反应发生率方面,观察组发生例数显著低于对照组,差异有统计学意义(P<0.05)。结论对骨髓增生异常综合征患者用地西他滨进行化疗在病情缓解方面有积极意义,安全性高,值得推广。

Objective To understand the control effect of disitabine in patients with myelodysplastic syndrome and the occurrence of discomfort symptoms. Methods Patients with myelodysplastic syndromes admitted to our hospital from 2014 to 2017 were included in the study. 12 patients were randomly selected according to their admission time. 6 patients in each group were divided into the control group and the observation group, the control group was treated with traditional chemotherapy, and the observation group was treated with dicitabine. To compare the value of two schemes in patients with myelodysplastic syndrome. Results After the course of treatment, the evaluation value of the two regimens was evaluated. The effective rate was 83.3% in the observation group and 66.7% in the control group. The observation group had superiority but the difference between the groups was not statistically significant（P〈 0.05）. The rate of observation group was significantly superior（P〈 0.05）; in the incidence of various adverse reactions, the number of cases observed in the observation group was significantly lower than the control group, the difference was statistically significant（P〈 0.05）. Conclusion Chemotherapy with sitagibine in patients with myelodysplastic syndrome has positive significance in terms of remission, safety, and worthy of promotion.